Disclosed is a use of a therapeutically effective amount of enterically-protected crofelemer for the manufacture of a medicament for treating constipation-predominant irritable bowel syndrome (c-IBS) or alternating constipation-predominant/diarrhoea predominant irritable bowel syndrome (a-IBS), in which the medicament is formulated for oral administration.
